PROCEPT BioRobotics Corporation (PRCT)

Market Cap	2.67B
Revenue (ttm)	136.19M
Net Income (ttm)	-105.90M
Shares Out	50.96M
EPS (ttm)	-2.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	512,345
Open	53.65
Previous Close	53.75
Day's Range	51.94 - 54.79
52-Week Range	24.83 - 54.79
Beta	1.01
Analysts	Strong Buy
Price Target	45.83 (-12.67%)
Earnings Date	May 1, 2024

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is he...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 626
• Stock Exchange: NASDAQ
• Ticker Symbol: PRCT

Financial Performance

In 2023, PRCT's revenue was $136.19 million, an increase of 81.55% compared to the previous year's $75.01 million. Losses were -$105.90 million, 21.5% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PRCT stock is "Strong Buy." The 12-month stock price forecast is $45.83, which is a decrease of -12.67% from the latest price.

Price Target

$45.83

(-12.67% downside)

Analyst Consensus: Strong Buy